HHV8
MCID: KPS004
MIFTS: 76

Kaposi Sarcoma (HHV8)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 57 12 73 20 58 36 54 42 15 70 32
Kaposi Sarcoma, Susceptibility to 57 29 13 6
Kaposi's Sarcoma 12 20 15 17
Angiofollicular Ganglionic Hyperplasia 58 70
Kaposi's Sarcoma of Soft Tissue 12 70
Kaposi's Sarcoma of Palate 12 70
Kaposi's Sarcoma of Lung 12 70
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 57
Multiple Idiopathic Pigmented Hemangiosarcoma 57
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 39
Angiofollicular Lymph Hyperplasia 58
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 70
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 20
Non-Aids-Related Kaposi Sarcoma 70
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 20
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 20
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 70
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 20
Castleman Disease 58
Sarcoma, Kaposi 44
Hhv8 20
Kshv 20

Characteristics:

Orphanet epidemiological data:

58
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8632
OMIM® 57 148000
KEGG 36 H00041
MeSH 44 D012514
MESH via Orphanet 45 C536362 D005871 D012514
UMLS via Orphanet 71 C0017531 C0036220 C2931179
UMLS 70 C0017531 C0036220 C0153560 more

Summaries for Kaposi Sarcoma

GARD : 20 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions ( macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy ( immunotherapy ). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi sarcoma, susceptibility to, is related to human herpesvirus 8 and sarcoma, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Bleomycin and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and lung, and related phenotypes are recurrent herpes and neoplasm of the skin

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM® : 57 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000) (Updated 05-Apr-2021)

MedlinePlus : 42 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS medicines. NIH: National Cancer Institute

KEGG : 36 Kaposi sarcoma (KS) is an angioproliferative disease classified into classic KS, endemic KS, iatrogenic KS, and HIV-associated KS (HIV-KS), however, share the same histological traits and are all associated with infection by the human herpesvirus 8 (HHV8; also known as KSHV). Evidence indicates that KS progression occurs upon the deregulated expression of anti-apoptotic genes (Bcl-2), oncogenes (c-myc, c-int, ras) and oncosuppressor genes (TP53), and is associated with the long-lasting expression of HHV8 latency genes (LANA, v-cyc D, v-FLIP, Kaposin). All these genes are, in fact, expressed or altered in most KS spindle cells in the nodular-late stage of KS. Bcl-2 acts as a major KS progression factor, and TP53 and c-myc may also have a role in disease progression. HHV8 latency gene products may be involved in KS progression due to their capability of promoting cell growth by direct effects or antiapoptotic effects.

Wikipedia : 73 Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1086, show less)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 33.2 IL6ST IL6-AS1 IL6
2 sarcoma 32.2 VEGFA TP53 TNFRSF4 STAT3 PDGFB MYC
3 acquired immunodeficiency syndrome 32.1 TP53 MYC IL6 IFNA2
4 castleman disease 32.0 VEGFA IL6ST IL6
5 immune deficiency disease 31.6 IRF3 IL6 IFNB1 CXCL1 CCR8 AKT1
6 angiosarcoma 31.4 VEGFA TP53 MYC
7 lymphoma, non-hodgkin, familial 31.2 TP53 STAT3 MYC IL6 CDK6 AKT1
8 lymphangioma 31.2 VEGFA TP53 STAT3 MYC IFNA2
9 poems syndrome 31.2 VEGFA IL6 FGF2
10 monoclonal gammopathy of uncertain significance 31.1 TP53 MYC IL6
11 bronchiolitis obliterans 31.1 PDGFB IL6 CXCL8
12 intussusception 31.1 VEGFA IL6 FGF2
13 diffuse large b-cell lymphoma 31.0 VEGFA TP53 STAT3 MYC IL6 AKT1
14 neutropenia 31.0 TP53 IL6 IFNA2 CXCL8
15 thrombocytopenia 30.9 STIM1 STAT3 IL6 IFNB1 IFNA2 CXCL8
16 hemangioma 30.9 VEGFA TP53 PDGFB MYC IL6 IFNA2
17 burkitt lymphoma 30.9 TP53 STAT3 MYC IRF3 IL6
18 diarrhea 30.9 IL6 IFNB1 IFNA2 CXCL8
19 vascular cancer 30.9 VEGFA TP53 IFNA2 FGF2
20 skin disease 30.9 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
21 exanthem 30.8 VEGFA IL6 CXCL8 AKT1
22 vaccinia 30.8 TP53 IRF3 IL6 IFNB1
23 pericardial effusion 30.8 VEGFA IL6 FGF2
24 gastritis 30.8 TP53 IL6 CXCL8 CXCL1
25 myeloma, multiple 30.8 VEGFA TP53 STAT3 MYC IL6 FGF2
26 anogenital venereal wart 30.8 TP53 IFNB1 IFNA2
27 fibrosarcoma 30.8 TP53 PDGFB MYC FGF2
28 t-cell lymphoblastic leukemia/lymphoma 30.8 TNFRSF4 STAT3 MYC CDK6 AKT1
29 skin carcinoma 30.7 VEGFA TP53 STAT3 MYC IL6 IFNB1
30 pleural disease 30.7 VEGFA TP53 IL6 CXCL8
31 papilledema 30.7 VEGFA TP53 STAT3
32 varicose veins 30.7 VEGFA IL6 CXCL8
33 rheumatoid arthritis 30.6 VEGFA IL6ST IL6 IFNB1 CXCL8 CXCL1
34 osteosclerotic myeloma 30.6 VEGFA IL6
35 leukemia, chronic lymphocytic 30.6 VEGFA TP53 STAT3 MYC IL6 AKT1
36 hepatitis c 30.6 STAT3 IRF3 IFNB1 IFNA2
37 esophagitis 30.6 TP53 IL6 CXCL8
38 dysentery 30.6 IL6 IFNA2 CXCL8
39 mantle cell lymphoma 30.6 VEGFA TP53 STAT3 MYC IL6 CDK6
40 basal cell carcinoma 30.6 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
41 aplastic anemia 30.6 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
42 combined immunodeficiency 30.6 VEGFA TNFRSF4 STIM1 STAT3 IL6 CXCL8
43 arteriovenous malformations of the brain 30.6 VEGFA IL6-AS1 IL6
44 retinal detachment 30.5 VEGFA PDGFB IL6 FGF2 CXCL8
45 human cytomegalovirus infection 30.5 IRF3 IL6 CXCL8
46 nervous system disease 30.5 VEGFA TP53 MYC IL6 IFNB1 FGF2
47 central nervous system lymphoma 30.5 TP53 MYC IL6
48 peripheral artery disease 30.5 VEGFA IL6 FGF2
49 nasopharyngeal carcinoma 30.5 VEGFA TP53 STAT3 MYC AKT1
50 allergic disease 30.5 TNFRSF4 STAT3 IL6 CXCL8
51 mature t-cell and nk-cell lymphoma 30.5 TP53 STAT3 MYC
52 bone inflammation disease 30.5 VEGFA STAT3 IL6 CXCL8
53 stomatitis 30.5 IL6 IFNB1 IFNA2 CXCL8
54 fasciitis 30.5 TP53 IL6 CXCL8
55 gastric ulcer 30.5 TP53 IL6 FGF2 CXCL8
56 tonsillitis 30.5 IL6 CXCL8 CXCL1
57 arthritis 30.5 VEGFA STAT3 IL6ST IL6 IFNB1 CXCL8
58 viral encephalitis 30.5 VEGFA IL6 IFNB1 CXCL8
59 plasmacytoma 30.5 VEGFA MYC IL6ST IL6 AKT1
60 neovascular glaucoma 30.5 VEGFA FGF2 CXCL8
61 sezary's disease 30.5 TP53 STAT3 MYC IFNA2
62 yellow fever 30.5 IL6 IFNB1 CXCL1
63 prostatitis 30.5 TP53 IL6 CXCL8
64 multiple sclerosis 30.5 STAT3 IL6 IFNB1 CXCL8 CXCL1 CCR8
65 macroglobulinemia 30.5 TP53 IL6 AKT1
66 pheochromocytoma 30.4 VEGFA STAT3 MYC IL6 FGF2
67 adult respiratory distress syndrome 30.4 IL6 IFNA2 CXCL8 CXCL1
68 autoimmune disease 30.4 TNFRSF4 STAT3 IL6 IFNB1 CXCL8
69 viral infectious disease 30.4 IRF3 IL6 IFNB1 IFNA2 CXCL8
70 keratitis, hereditary 30.4 VEGFA IL6 FGF2 CXCL8 CXCL1
71 macular retinal edema 30.4 VEGFA IL6 IFNB1 CXCL8
72 squamous cell carcinoma 30.4 VEGFA TP53 STAT3 MYC AKT1
73 cystitis 30.4 VEGFA TP53 IL6 CXCL8 CXCL1
74 myelofibrosis 30.4 VEGFA TP53 STAT3 IFNA2 FGF2 CXCL8
75 bacterial pneumonia 30.4 IL6 CXCL8 CXCL1
76 covid-19 30.4 IL6 IFNB1 IFNA2 CXCL8
77 tuberous sclerosis 30.3 VEGFA TP53 MYC AKT1
78 gingival overgrowth 30.3 TP53 PDGFB IL6 FGF2 CXCL8
79 glioblastoma 30.3 VEGFA TP53 STAT3 PDGFB MYC CDK6
80 amyotrophic lateral sclerosis 1 30.3 VEGFA MYC IL6 IFNB1 FGF2 CXCL1
81 secondary progressive multiple sclerosis 30.3 VEGFA IFNB1 CCR8
82 renal cell carcinoma, nonpapillary 30.3 VEGFA TP53 STAT3 IFNA2 FGF2 AKT1
83 liver cirrhosis 30.3 VEGFA TP53 IL6 IFNA2 CXCL8 AKT1
84 lichen planus 30.3 TP53 IL6 CXCL8
85 retinal vascular disease 30.3 VEGFA IL6 FGF2 CXCL8 AKT1
86 suppression of tumorigenicity 12 30.3 VEGFA TP53 MYC AKT1
87 cholangiocarcinoma 30.3 VEGFA TP53 STAT3 IL6 AKT1
88 clear cell renal cell carcinoma 30.3 VEGFA TP53 STAT3 MYC IL6 AKT1
89 connective tissue disease 30.3 VEGFA TP53 IL6 CXCL8 AKT1
90 adenocarcinoma 30.3 VEGFA TP53 STAT3 MYC AKT1
91 polycystic kidney disease 30.2 VEGFA TP53 STAT3 MYC FGF2 AKT1
92 alcoholic hepatitis 30.2 IL6 CXCL8 CXCL1
93 hepatitis b 30.2 TP53 STAT3 MYC IL6 IFNB1 IFNA2
94 inflammatory bowel disease 30.2 VEGFA TP53 TNFRSF4 STAT3 MYC IL6ST
95 pancreatic adenocarcinoma 30.2 VEGFA TP53 STAT3 IL6 FGF2 AKT1
96 t-cell acute lymphoblastic leukemia 30.2 TP53 MYC IL6 CDK6 AKT1
97 melanoma 30.2 VEGFA TP53 STAT3 PDGFB MYC IFNB1
98 peripheral nervous system disease 30.1 VEGFA TP53 STAT3 MYC IL6 IFNB1
99 mature b-cell neoplasm 30.1 TP53 MYC IL6
100 adult t-cell leukemia 30.1 TP53 STAT3 MYC
101 polyarteritis nodosa 30.1 IL6 IFNA2 FGF2 ADA2
102 bladder cancer 30.1 VEGFA TP53 STAT3 MYC IFNA2 FGF2
103 skin melanoma 30.1 VEGFA TP53 STAT3 MYC IL6 IFNA2
104 type 2 diabetes mellitus 30.1 VEGFA TP53 STAT3 IL6-AS1 IL6 FGF2
105 leukemia, acute myeloid 30.1 VEGFA TP53 STAT3 MYC IL6 FGF2
106 myelodysplastic syndrome 30.0 VEGFA TP53 STAT3 MYC IL6 FGF2
107 pulmonary fibrosis, idiopathic 30.0 VEGFA TP53 STAT3 PDGFB IL6 FGF2
108 pancreatic cancer 30.0 VEGFA TP53 STAT3 MYC IL6 FGF2
109 systemic lupus erythematosus 30.0 VEGFA TP53 TNFRSF4 STAT3 IRF3 IL6
110 ovarian cancer 29.9 VEGFA TP53 STAT3 MYC IL6 FGF2
111 prostate cancer 29.8 VEGFA TP53 STAT3 PDGFB MYC IL6
112 hepatocellular carcinoma 29.7 VEGFA TP53 STAT3 MYC IL6 IFNB1
113 immunodeficiency 16 11.6
114 endemic kaposi sarcoma 11.5
115 spindle cell sarcoma 11.4
116 human herpesvirus 8-related disorder 11.3
117 colon kaposi sarcoma 11.3
118 dermatofibrosarcoma protuberans 11.2
119 rectum kaposi's sarcoma 11.1
120 littoral cell angioma of the spleen 11.1
121 glomeruloid hemangioma 11.0
122 human immunodeficiency virus type 1 10.9
123 lymphoma aids related 10.8
124 multicentric castleman disease 10.8
125 lymphoma 10.7
126 mixed lacrimal gland cancer 10.6 STAT3 IL6
127 gorham's disease 10.6 VEGFA IL6 IFNA2
128 ulcer of lower limbs 10.6 VEGFA IL6 FGF2
129 hyper ige recurrent infection syndrome 1 10.6 STAT3 IL6ST IL6
130 b-cell lymphoma 10.5
131 capillary disease 10.5 VEGFA IL6 FGF2
132 nodular goiter 10.5 VEGFA TNFRSF4 IL6
133 lymphoma, hodgkin, classic 10.5
134 idiopathic anterior uveitis 10.5 IL6 CXCL8
135 ischemic bone disease 10.5 VEGFA IL6 FGF2
136 juvenile nasopharyngeal angiofibroma 10.5 VEGFA MYC FGF2
137 endophthalmitis 10.5 VEGFA IL6 CXCL8
138 retinal vascular occlusion 10.5 VEGFA IL6 CXCL8
139 drug-induced lupus erythematosus 10.5 VEGFA IL6 CXCL8
140 hereditary lymphedema i 10.5
141 kshv inflammatory cytokine syndrome 10.5
142 macular holes 10.5 VEGFA IL6 CXCL8
143 hantavirus hemorrhagic fever with renal syndrome 10.5 VEGFA IL6 IFNB1
144 apnea, obstructive sleep 10.5 VEGFA IL6 CXCL8
145 retinal artery occlusion 10.5 VEGFA IL6 CXCL8
146 streptococcal toxic-shock syndrome 10.5 IL6 CXCL8
147 acute transverse myelitis 10.5 IL6 CXCL8
148 tendinitis 10.5 VEGFA PDGFB IL6
149 anal carcinoma in situ 10.5 TP53 MYC
150 diabetic macular edema 10.5 VEGFA IL6 FGF2
151 rosacea 10.5 VEGFA IL6 CXCL8
152 liver benign neoplasm 10.5 TP53 STAT3 IL6ST
153 conjunctival disease 10.5 IL6ST IL6 IFNA2 CXCL8
154 spherocytosis, type 5 10.5 STAT3 IL6 AKT1
155 vein disease 10.5 VEGFA IL6 CXCL8
156 opportunistic mycosis 10.5 STAT3 IL6 CXCL8
157 hantavirus pulmonary syndrome 10.5 VEGFA IRF3 IFNB1
158 lung giant cell carcinoma 10.5 VEGFA MYC CXCL8
159 cytokine deficiency 10.5
160 blood group, globoside system 10.5 VEGFA IL6 FGF2 CXCL8
161 gum cancer 10.5 TP53 MYC IL6
162 blood protein disease 10.5 VEGFA MYC IL6
163 fungal infectious disease 10.5 STAT3 IL6 CXCL8
164 retinal vein occlusion 10.5 VEGFA IL6 CXCL8
165 viral pneumonia 10.5 IL6 IFNB1 CXCL8
166 common cold 10.5 IL6 IFNA2 CXCL8
167 ileitis 10.5 STAT3 IL6 CCR8
168 acute gonococcal cervicitis 10.5 IL6 CXCL8
169 klebsiella pneumonia 10.5 IL6 CXCL8 CXCL1
170 primary peritoneal carcinoma 10.5 VEGFA TP53 CXCL8
171 hepatic veno-occlusive disease 10.5 VEGFA FGF2 CXCL8
172 placental insufficiency 10.5 VEGFA IL6 FGF2 CXCL8
173 hyper ige syndrome 10.5 STAT3 IL6ST IL6 CXCL8
174 degeneration of macula and posterior pole 10.5 VEGFA IL6 FGF2
175 lymphocytic choriomeningitis 10.5 IRF3 IL6 CXCL8
176 sapho syndrome 10.5 VEGFA TP53 CXCL8
177 streptococcus pneumonia 10.5 IL6 IFNB1 CXCL8
178 corneal disease 10.5 VEGFA IL6 FGF2 CXCL8
179 pediatric angiosarcoma 10.5 VEGFA TP53
180 listeriosis 10.5 IRF3 IL6 IFNB1
181 preterm premature rupture of the membranes 10.5 IL6ST IL6 CXCL8
182 mucosal melanoma 10.5 VEGFA TP53 IFNA2
183 bacteriuria 10.5 IL6 CXCL8 CXCL1
184 endometritis 10.5 IL6 CXCL8 CXCL1
185 lichen disease 10.5 TP53 IL6 CXCL8
186 decubitus ulcer 10.5 VEGFA PDGFB IL6 FGF2
187 myelitis 10.5 IL6 IFNB1 CXCL8
188 microvascular complications of diabetes 1 10.5 VEGFA IL6 FGF2 CXCL8
189 chronic ulcer of skin 10.5 VEGFA PDGFB IL6 FGF2
190 vaginal disease 10.5 TP53 IL6 CXCL8
191 cowpox 10.5 IL6 CXCL8 CXCL1
192 limb ischemia 10.5 VEGFA IL6 FGF2
193 hyper-ige recurrent infection syndrome 1, autosomal dominant 10.5 STAT3 IL6ST
194 optic neuritis 10.5 VEGFA IL6 CXCL8
195 anus disease 10.5 TP53 IL6 CXCL8
196 fuchs' heterochromic uveitis 10.5 IL6 CXCL8
197 rectal disease 10.5 TP53 IL6 CXCL8
198 fallopian tube disease 10.5 VEGFA TP53 IL6 CXCL8
199 acute cystitis 10.5 IL6 CXCL8 CXCL1
200 adenomyosis 10.5 VEGFA TP53 IL6 CXCL8
201 chorioamnionitis 10.5 VEGFA IL6 CXCL8
202 exudative vitreoretinopathy 1 10.5 VEGFA PDGFB IL6 FGF2
203 coronavirus infectious disease 10.5 IRF3 IL6 IFNB1 CXCL8
204 pancreatic ductal carcinoma 10.4 VEGFA TP53 STAT3 MYC
205 atrophic gastritis 10.4 TP53 STAT3 IL6 CXCL8
206 autoimmune disease of musculoskeletal system 10.4 STAT3 IL6 IFNB1 CXCL8
207 uveal disease 10.4 VEGFA IL6 CXCL8
208 dengue hemorrhagic fever 10.4 IL6 IFNB1 CXCL8
209 meningitis 10.4 VEGFA IL6 CXCL8 CXCL1
210 severe acute respiratory syndrome 10.4 IRF3 IL6 IFNB1 CXCL8
211 bladder tuberculosis 10.4 IFNB1 IFNA2
212 colorectal adenocarcinoma 10.4 VEGFA TP53 STAT3 MYC
213 fallopian tube carcinoma 10.4 VEGFA TP53 MYC
214 cystadenocarcinoma 10.4 VEGFA TP53 AKT1
215 uterine benign neoplasm 10.4 VEGFA TP53 AKT1
216 reproductive organ benign neoplasm 10.4 VEGFA TP53 AKT1
217 human papillomavirus infectious disease 10.4 TP53 IFNB1
218 rhabdoid cancer 10.4 TP53 STIM1 MYC
219 polycythemia vera 10.4 TP53 STAT3 IL6 IFNA2
220 respiratory system benign neoplasm 10.4 TP53 MYC AKT1
221 herpangina 10.4 TP53 IRF3 IL6 IFNB1
222 duodenal ulcer 10.4 IL6 CXCL8 CXCL1
223 lens disease 10.4 VEGFA IL6 CXCL8
224 lung adenoma 10.4 TP53 MYC AKT1
225 newcastle disease 10.4 TP53 IRF3 IFNB1
226 bacterial meningitis 10.4 IL6 CXCL8 CXCL1
227 ovarian cystadenocarcinoma 10.4 TP53 MYC AKT1
228 vitreous disease 10.4 VEGFA PDGFB IL6 FGF2 CXCL8
229 pleural cancer 10.4 VEGFA TP53 AKT1
230 cardiovascular organ benign neoplasm 10.4 VEGFA TP53 FGF2 AKT1
231 legionellosis 10.4 IL6 CXCL8 CXCL1
232 endometrial adenocarcinoma 10.4 VEGFA TP53 FGF2 AKT1
233 germ cell and embryonal cancer 10.4 TP53 MYC FGF2
234 frontal lobe neoplasm 10.4 TP53 MYC
235 uterine corpus cancer 10.4 TP53 MYC AKT1
236 skin papilloma 10.4 TP53 STAT3 MYC AKT1
237 lymphoproliferative syndrome 10.4
238 pyogenic granuloma 10.4
239 microvascular complications of diabetes 5 10.4 VEGFA PDGFB FGF2 AKT1
240 ovary adenocarcinoma 10.4 VEGFA TP53 MYC AKT1
241 pre-malignant neoplasm 10.4 VEGFA TP53 MYC AKT1
242 ductal carcinoma in situ 10.4 VEGFA TP53 MYC AKT1
243 colorectal adenoma 10.4 VEGFA TP53 MYC IL6 CXCL8
244 mumps 10.4 IL6 IFNB1 CXCL8
245 hemorrhagic disease 10.4 VEGFA IRF3 IL6 IFNB1 CXCL8
246 malignant ovarian surface epithelial-stromal neoplasm 10.4 VEGFA TP53 MYC AKT1
247 ovary epithelial cancer 10.4 VEGFA TP53 MYC AKT1
248 skeletal muscle cancer 10.4 TP53 MYC AKT1
249 cervix carcinoma 10.4 TP53 STAT3 MYC AKT1
250 muscle cancer 10.4 TP53 MYC AKT1
251 retinal cancer 10.4 TP53 MYC CDK6 AKT1
252 tongue squamous cell carcinoma 10.4 VEGFA TP53 STAT3 AKT1
253 thyroid gland follicular carcinoma 10.4 VEGFA TP53 MYC AKT1
254 autonomic nervous system neoplasm 10.4 VEGFA TP53 MYC AKT1
255 peripheral nervous system neoplasm 10.4 VEGFA TP53 MYC AKT1
256 cell type benign neoplasm 10.4 VEGFA TP53 MYC AKT1
257 serous cystadenocarcinoma 10.4 VEGFA TP53 AKT1
258 central nervous system cancer 10.4 VEGFA TP53 MYC AKT1
259 ocular cancer 10.4 TP53 MYC CDK6 AKT1
260 colonic benign neoplasm 10.4 TP53 STAT3 MYC IL6 AKT1
261 reactive arthritis 10.4 IL6 IFNB1 CXCL8
262 gastrointestinal system benign neoplasm 10.4 TP53 STAT3 MYC IL6 AKT1
263 amelogenesis imperfecta, type ig 10.4 VEGFA TP53 MYC IL6 AKT1
264 amelogenesis imperfecta 10.4 VEGFA TP53 MYC IL6 AKT1
265 connective tissue cancer 10.4 VEGFA TP53 MYC AKT1
266 tafro syndrome 10.4
267 venous insufficiency 10.4
268 lymphopenia 10.4
269 rare lymphatic malformation 10.4
270 estrogen-receptor positive breast cancer 10.4 VEGFA TP53 STAT3 MYC AKT1
271 blood platelet disease 10.4 VEGFA TP53 IL6 CXCL8 AKT1
272 bone osteosarcoma 10.4 TP53 MYC AKT1
273 b cell prolymphocytic leukemia 10.4 TP53 MYC
274 blood coagulation disease 10.4 VEGFA TP53 IL6 CXCL8 AKT1
275 tongue disease 10.4 VEGFA TP53 STAT3 MYC AKT1
276 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.4 VEGFA TP53 MYC IL6 AKT1
277 hair disease 10.4 VEGFA IL6 AKT1
278 cervical squamous cell carcinoma 10.4 VEGFA TP53 STAT3 MYC AKT1
279 penile disease 10.4 TP53 IL6 IFNB1 IFNA2 AKT1
280 high grade glioma 10.4 VEGFA TP53 STAT3 FGF2
281 melanoma, cutaneous malignant 1 10.4 TP53 MYC IFNA2 CDK6 AKT1
282 igg4-related disease 10.4
283 bile duct cancer 10.4 VEGFA TP53 IL6 AKT1
284 pancreatic ductal adenocarcinoma 10.4 VEGFA TP53 STAT3 MYC AKT1
285 in situ carcinoma 10.3 TP53 MYC AKT1
286 arteriovenous malformation 10.3
287 pustulosis of palm and sole 10.3
288 psoriasis 10.3
289 adenoid cystic carcinoma 10.3 VEGFA TP53 STAT3 MYC AKT1
290 melanoma, uveal 10.3 VEGFA TP53 MYC AKT1
291 gliosarcoma 10.3 VEGFA TP53 IFNB1 FGF2 AKT1
292 macular degeneration, age-related, 1 10.3 VEGFA IL6 FGF2 CXCL8 AKT1
293 intestinal benign neoplasm 10.3 VEGFA TP53 STAT3 MYC IL6 AKT1
294 biliary tract disease 10.3 VEGFA TP53 STAT3 MYC IL6 AKT1
295 bone marrow cancer 10.3 VEGFA TP53 STAT3 MYC IL6 AKT1
296 integumentary system disease 10.3 VEGFA TP53 STAT3 IL6 CXCL8 AKT1
297 hepatoblastoma 10.3 VEGFA TP53 STAT3 MYC IL6 AKT1
298 autoimmune disease of gastrointestinal tract 10.3 STAT3 IL6 CXCL8
299 plasmablastic lymphoma 10.3
300 pancytopenia 10.3
301 splenomegaly 10.3
302 malignant astrocytoma 10.3 VEGFA TP53 STAT3 MYC FGF2 AKT1
303 anaplastic large cell lymphoma 10.3
304 bone sarcoma 10.3 VEGFA TP53 MYC IL6 CXCL8 AKT1
305 kidney cancer 10.3 VEGFA TP53 IFNA2 FGF2 CXCL8 AKT1
306 cervical adenocarcinoma 10.3 TP53 MYC AKT1
307 autosomal genetic disease 10.3 VEGFA TP53 MYC IL6 CXCL8 AKT1
308 brain cancer 10.3 VEGFA TP53 STAT3 MYC FGF2 AKT1
309 placenta disease 10.3 VEGFA IL6 CXCL8
310 congenital myasthenic syndrome 10.3 TP53 STIM1 MYC IL6 CXCL8 AKT1
311 toxoplasmosis 10.3
312 thyroid gland cancer 10.3 VEGFA TP53 MYC AKT1
313 sleep apnea 10.3 VEGFA IL6 CXCL8
314 breast carcinoma in situ 10.3 VEGFA TP53 MYC IL6ST IL6 FGF2
315 chronic venous insufficiency 10.3
316 lung cancer susceptibility 3 10.3 VEGFA TP53 STAT3 MYC AKT1
317 spinal disease 10.3 VEGFA TP53 STAT3 MYC IL6 FGF2
318 ovarian serous cystadenocarcinoma 10.3 VEGFA TP53 AKT1
319 pulmonary hypertension, primary, 1 10.3
320 inflammatory myofibroblastic tumor 10.3
321 bronchiolitis 10.3
322 neuroretinitis 10.3
323 leukocyte disease 10.3 VEGFA TP53 STAT3 MYC IL6 CXCL8
324 cataract 10.3 VEGFA TP53 IL6 FGF2 CXCL8 AKT1
325 hypotrichosis 1 10.3 VEGFA TP53 MYC IL6 FGF2 CXCL8
326 essential thrombocythemia 10.3 VEGFA TP53 STAT3 MYC IL6 IFNA2
327 osteoporosis 10.3 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
328 bacillary angiomatosis 10.3
329 respiratory failure 10.3
330 purpura 10.3
331 syphilis 10.3
332 human immunodeficiency virus infectious disease 10.3
333 angiomatosis 10.3
334 sting-associated vasculopathy with onset in infancy 10.3 IRF3 IFNB1 ADA2
335 infratentorial cancer 10.3 TP53 MYC AKT1
336 squamous cell carcinoma, head and neck 10.3 VEGFA TP53 STAT3 MYC FGF2 CXCL8
337 thrombocytosis 10.3
338 myocardial infarction 10.2 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
339 interstitial lung disease 10.2
340 parapsoriasis 10.2
341 cytomegalovirus retinitis 10.2
342 retinitis 10.2
343 visceral leishmaniasis 10.2
344 rasopathy 10.2 TP53 STAT3 MYC IRF3 IFNB1 FGF2
345 phlebotomus fever 10.2 IRF3 IFNB1
346 endometrial cancer 10.2 VEGFA TP53 STAT3 MYC FGF2 CDK6
347 neuroblastoma 10.2 VEGFA TP53 STAT3 MYC IL6 FGF2
348 nephrotic syndrome 10.2
349 amyloidosis aa 10.2
350 thrombotic microangiopathy 10.2
351 malaria 10.2
352 candidiasis 10.2
353 keratosis 10.2
354 dermatitis 10.2
355 sensory system disease 10.2 VEGFA TP53 MYC IL6 FGF2 CXCL8
356 hypertension, essential 10.2 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
357 eye disease 10.2 VEGFA TP53 MYC IL6 FGF2 CXCL8
358 ewing sarcoma 10.2 VEGFA TP53 STAT3 PDGFB MYC IL6
359 active peptic ulcer disease 10.2
360 myeloid leukemia 10.2
361 chlamydia 10.2
362 hepatitis a 10.2
363 polyneuropathy 10.2
364 chickenpox 10.2
365 microcytic anemia 10.2
366 acute kidney failure 10.2
367 conjunctival degeneration 10.2 TP53 IFNA2
368 dowling-degos disease 1 10.2
369 sarcoidosis 1 10.2
370 deficiency anemia 10.2
371 hemophagocytic lymphohistiocytosis 10.2
372 colitis 10.2
373 pemphigoid 10.2
374 cryptococcosis 10.2
375 glomerulonephritis 10.2
376 hemolytic anemia 10.2
377 bullous pemphigoid 10.2
378 herpes simplex 10.2
379 ulcerative colitis 10.2
380 alopecia 10.2
381 dysphagia 10.2
382 hemangiopericytoma, malignant 10.2
383 proteasome-associated autoinflammatory syndrome 1 10.2
384 cheilitis 10.2
385 hairy cell leukemia 10.2
386 testicular cancer 10.2
387 central nervous system disease 10.2
388 rhabdomyosarcoma 10.2 VEGFA TP53 STIM1 STAT3 PDGFB MYC
389 meningioma, familial 10.1
390 intracranial meningioma 10.1
391 secretory meningioma 10.1
392 lymphoplasmacyte-rich meningioma 10.1
393 neuropathy 10.1
394 behcet syndrome 10.1 VEGFA IL6 IFNB1 IFNA2 CXCL8 ADA2
395 pemphigus foliaceus 10.1
396 bowen's disease 10.1
397 retinoblastoma 10.1
398 myasthenia gravis 10.1
399 membranous nephropathy 10.1
400 cutaneous t cell lymphoma 10.1
401 osteomyelitis 10.1
402 pneumocystosis 10.1
403 oral candidiasis 10.1
404 pulmonary tuberculosis 10.1
405 merkel cell carcinoma 10.1
406 secondary syphilis 10.1
407 cutaneous fibrous histiocytoma 10.1
408 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
409 vasculitis 10.1
410 48,xyyy 10.1
411 hemangioendothelioma 10.1
412 leukemia, t-cell, chronic 10.1
413 hypoxia 10.1
414 rare tumor 10.1
415 autoimmune pancreatitis 10.1
416 lymphoblastic lymphoma 10.1
417 granulomatosis with polyangiitis 10.1
418 erythema elevatum diutinum 10.1
419 tinea pedis 10.1
420 mesenchymal cell neoplasm 10.1
421 cholangitis 10.1
422 angioimmunoblastic lymphadenopathy with dysproteinemia 10.1
423 esophageal cancer 10.1 VEGFA TP53 STAT3 PDGFB MYC IL6
424 medulloblastoma 10.1 VEGFA TP53 STAT3 PDGFB MYC IL6
425 lymphadenitis 10.0
426 chronic kidney disease 10.0
427 lupus erythematosus 10.0
428 pityriasis rosea 10.0
429 diabetes mellitus 10.0
430 plasma cell leukemia 10.0
431 hemophilia 10.0
432 aids dementia complex 10.0
433 post-transplant lymphoproliferative disease 10.0
434 secondary hemophagocytic lymphohistiocytosis 10.0
435 primary cutaneous anaplastic large cell lymphoma 10.0
436 disease of mental health 10.0 VEGFA TP53 STAT3 MYC IL6 IFNB1
437 langerhans cell histiocytosis 10.0
438 paraganglioma 10.0
439 iron deficiency anemia 10.0
440 neuroendocrine tumor 10.0
441 proliferative glomerulonephritis 10.0
442 pancreatitis 10.0
443 myositis 10.0
444 thrombocytopenic purpura, autoimmune 10.0
445 lymphoma, mucosa-associated lymphoid type 10.0
446 factor vii deficiency 10.0
447 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
448 leprosy 3 10.0
449 ataxia and polyneuropathy, adult-onset 10.0
450 dermatitis, atopic 10.0
451 cervical cancer 10.0
452 mycobacterium tuberculosis 1 10.0
453 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
454 psoriasis 14, pustular 10.0
455 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
456 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
457 pulmonary hypertension 10.0
458 asymptomatic neurosyphilis 10.0
459 thrombotic thrombocytopenic purpura 10.0
460 bartonellosis 10.0
461 pertussis 10.0
462 t cell deficiency 10.0
463 cat-scratch disease 10.0
464 hemopericardium 10.0
465 penis sarcoma 10.0
466 conn's syndrome 10.0
467 common variable immunodeficiency 10.0
468 plica syndrome 10.0
469 marasmus 10.0
470 cholestasis 10.0
471 extrahepatic cholestasis 10.0
472 vascular disease 10.0
473 hepatitis 10.0
474 lateral sclerosis 10.0
475 relapsing-remitting multiple sclerosis 10.0
476 lymphangiosarcoma 10.0
477 synovitis 10.0
478 contact dermatitis 10.0
479 granuloma annulare 10.0
480 cavernous hemangioma 10.0
481 spindle cell hemangioma 10.0
482 plasma cell neoplasm 10.0
483 end stage renal disease 10.0
484 lung disease 10.0
485 crohn's disease 10.0
486 actinic keratosis 10.0
487 molluscum contagiosum 10.0
488 hypereosinophilic syndrome 10.0
489 anca-associated vasculitis 10.0
490 hansen's disease 10.0
491 kaposiform hemangioendothelioma 10.0
492 microscopic polyangiitis 10.0
493 nephrogenic systemic fibrosis 10.0
494 neurosyphilis 10.0
495 pustular psoriasis 10.0
496 reactive angioendotheliomatosis 10.0
497 soft tissue sarcoma 10.0
498 virus associated hemophagocytic syndrome 10.0
499 hemophagocytic syndrome associated with an infection 10.0
500 myxoid liposarcoma 10.0 TP53 IL6 CXCL8
501 triiodothyronine receptor auxiliary protein 10.0
502 atherosclerosis susceptibility 10.0
503 multiple acyl-coa dehydrogenase deficiency 10.0
504 yemenite deaf-blind hypopigmentation syndrome 10.0
505 psoriatic arthritis 10.0
506 leukemia, chronic myeloid 10.0
507 leukemia, acute lymphoblastic 10.0
508 podoconiosis 10.0
509 erythema multiforme 10.0
510 oral squamous cell carcinoma 10.0
511 oral hairy leukoplakia 10.0
512 meningoencephalitis 10.0
513 esophageal candidiasis 10.0
514 anus cancer 10.0
515 median rhomboid glossitis 10.0
516 sclerosing cholangitis 10.0
517 glossitis 10.0
518 cryptosporidiosis 10.0
519 benign mesothelioma 10.0
520 substance abuse 10.0
521 liposarcoma 10.0
522 linitis plastica 10.0
523 conjunctivitis 10.0
524 scabies 10.0
525 miliary tuberculosis 10.0
526 hordeolum 10.0
527 lymph node disease 10.0
528 intravascular papillary endothelial hyperplasia 10.0
529 paresthesia 10.0
530 specific language disorder 10.0
531 marfan syndrome 9.9
532 hypertriglyceridemia, familial 9.9
533 hypercholesterolemia, familial, 1 9.9
534 gastrointestinal stromal tumor 9.9
535 aspergillosis 9.9
536 marginal zone b-cell lymphoma 9.9
537 adrenal gland pheochromocytoma 9.9
538 nodal marginal zone lymphoma 9.9
539 sialadenitis 9.9
540 interstitial nephritis 9.9
541 brucellosis 9.9
542 crescentic glomerulonephritis 9.9
543 optic nerve disease 9.9
544 agammaglobulinemia 9.9
545 acinar cell carcinoma 9.9
546 polyradiculoneuropathy 9.9
547 brain edema 9.9
548 nephrolithiasis 9.9
549 thyroiditis 9.9
550 evans' syndrome 9.9
551 nodal marginal zone b-cell lymphoma 9.9
552 thyroid carcinoma 9.9
553 breast cancer 9.9 VEGFA TP53 STIM1 STAT3 PDGFB MYC
554 human t-cell leukemia virus type 1 9.9
555 fibrosis of extraocular muscles, congenital, 1 9.9
556 b-cell growth factor 9.9
557 spondyloarthropathy 1 9.9
558 pfeiffer syndrome 9.9
559 schopf-schulz-passarge syndrome 9.9
560 prostatic hyperplasia, benign 9.9
561 pars planitis 9.9
562 allergic rhinitis 9.9
563 kawasaki disease 9.9
564 monocarboxylate transporter 1 deficiency 9.9
565 helix syndrome 9.9
566 chlamydia pneumonia 9.9
567 epstein-barr virus hepatitis 9.9
568 persistent generalized lymphadenopathy 9.9
569 pollen allergy 9.9
570 paraneoplastic pemphigus 9.9
571 rapidly involuting congenital hemangioma 9.9
572 chronic leukemia 9.9
573 gastric lymphoma 9.9
574 prostatic hypertrophy 9.9
575 cardiac tamponade 9.9
576 gastroparesis 9.9
577 inflammatory spondylopathy 9.9
578 acute leukemia 9.9
579 guillain-barre syndrome 9.9
580 miller fisher syndrome 9.9
581 chancroid 9.9
582 spinal cord lymphoma 9.9
583 hypothyroidism 9.9
584 cholera 9.9
585 pneumothorax 9.9
586 polyclonal hypergammaglobulinemia 9.9
587 prostatic adenoma 9.9
588 demyelinating disease 9.9
589 histiocytosis 9.9
590 mammary paget's disease 9.9
591 breast adenocarcinoma 9.9
592 mixed connective tissue disease 9.9
593 venous hemangioma 9.9
594 histiocytoid hemangioma 9.9
595 pulmonary venoocclusive disease 9.9
596 spondylitis 9.9
597 diverticulitis 9.9
598 rubella 9.9
599 neurofibroma 9.9
600 aphthous stomatitis 9.9
601 kikuchi disease 9.9
602 leukoplakia 9.9
603 lymphomatoid papulosis 9.9
604 oral cancer 9.9
605 primary central nervous system lymphoma 9.9
606 unicentric castleman disease 9.9
607 primary cutaneous b-cell lymphoma 9.9
608 primary cutaneous diffuse large b-cell lymphoma, leg type 9.9
609 b-cell non-hodgkin lymphoma 9.9
610 t-cell non-hodgkin lymphoma 9.9
611 endotheliitis 9.9
612 rare vascular tumor 9.9
613 discoid lupus erythematosus 9.9
614 intravascular large b-cell lymphoma 9.9
615 pemphigus vulgaris, familial 9.9
616 prader-willi syndrome 9.9
617 temporal arteritis 9.9
618 lichen sclerosus et atrophicus 9.9
619 leukemia, acute monocytic 9.9
620 klippel-trenaunay-weber syndrome 9.9
621 alcohol dependence 9.9
622 vitiligo-associated multiple autoimmune disease susceptibility 6 9.9
623 adrenocortical carcinoma, hereditary 9.9
624 anemia, autoimmune hemolytic 9.9
625 ascites, chylous 9.9
626 ataxia-telangiectasia 9.9
627 type 1 diabetes mellitus 9.9
628 mycosis fungoides 9.9
629 ocular motor apraxia 9.9
630 periodontitis, chronic 9.9
631 inflammatory bowel disease 1 9.9
632 insulin-like growth factor i 9.9
633 thymoma, familial 9.9
634 werner syndrome 9.9
635 body mass index quantitative trait locus 11 9.9
636 wiskott-aldrich syndrome 9.9
637 gonadoblastoma 9.9
638 retinitis pigmentosa 11 9.9
639 body mass index quantitative trait locus 9 9.9
640 body mass index quantitative trait locus 8 9.9
641 sickle cell anemia 9.9
642 rheumatoid arthritis, systemic juvenile 9.9
643 vitiligo-associated multiple autoimmune disease susceptibility 1 9.9
644 pulmonary disease, chronic obstructive 9.9
645 body mass index quantitative trait locus 4 9.9
646 body mass index quantitative trait locus 10 9.9
647 angioma, tufted 9.9
648 kala-azar 1 9.9
649 body mass index quantitative trait locus 7 9.9
650 hepatitis c virus 9.9
651 buruli ulcer 9.9
652 hamamy syndrome 9.9
653 body mass index quantitative trait locus 12 9.9
654 acute promyelocytic leukemia 9.9
655 body mass index quantitative trait locus 14 9.9
656 immunodeficiency 10 9.9
657 graft-versus-host disease 9.9
658 body mass index quantitative trait locus 18 9.9
659 neu-laxova syndrome 2 9.9
660 thrombocytopenia 6 9.9
661 lung disease, immunodeficiency, and chromosome breakage syndrome 9.9
662 body mass index quantitative trait locus 19 9.9
663 proteinuria, chronic benign 9.9
664 adrenal cortical carcinoma 9.9
665 disease by infectious agent 9.9
666 follicular lymphoma 9.9
667 connective tissue benign neoplasm 9.9
668 crohn's colitis 9.9
669 scoliosis 9.9
670 thrombosis 9.9
671 cutaneous candidiasis 9.9
672 mucositis 9.9
673 b-lymphoblastic leukemia/lymphoma 9.9
674 limbic encephalitis 9.9
675 antisynthetase syndrome 9.9
676 polymyositis 9.9
677 urinary tract infection 9.9
678 angioimmunoblastic t-cell lymphoma 9.9
679 cysticercosis 9.9
680 dermatomyositis 9.9
681 yaws 9.9
682 prolymphocytic leukemia 9.9
683 bacterial infectious disease 9.9
684 protein-losing enteropathy 9.9
685 filariasis 9.9
686 alport syndrome 9.9
687 erysipelas 9.9
688 tetanus 9.9
689 pulmonary edema 9.9
690 onchocerciasis 9.9
691 portal vein thrombosis 9.9
692 pulmonary alveolar proteinosis 9.9
693 filarial elephantiasis 9.9
694 entropion 9.9
695 leukemia 9.9
696 paracoccidioidomycosis 9.9
697 leiomyoma 9.9
698 telangiectasis 9.9
699 uveitis 9.9
700 gout 9.9
701 pure red-cell aplasia 9.9
702 obstructive jaundice 9.9
703 biliary atresia 9.9
704 lymphogranuloma venereum 9.9
705 squamous cell papilloma 9.9
706 plasmodium falciparum malaria 9.9
707 toxic shock syndrome 9.9
708 selective igg deficiency disease 9.9
709 gonadal dysgenesis 9.9
710 panniculitis 9.9
711 ichthyosis 9.9
712 histoplasmosis 9.9
713 malignant fibrous histiocytoma 9.9
714 hyperuricemia 9.9
715 leiomyosarcoma 9.9
716 rectum adenocarcinoma 9.9
717 constipation 9.9
718 colon adenocarcinoma 9.9
719 iron metabolism disease 9.9
720 papilloma 9.9
721 capillary hemangioma 9.9
722 nonspecific interstitial pneumonia 9.9
723 endometriosis 9.9
724 membranoproliferative glomerulonephritis 9.9
725 anuria 9.9
726 allergic contact dermatitis 9.9
727 gingivitis 9.9
728 proctitis 9.9
729 skin benign neoplasm 9.9
730 thymoma 9.9
731 cellulitis 9.9
732 vaginal discharge 9.9
733 pulmonary fibrosis 9.9
734 pituitary adenoma 9.9
735 adrenal carcinoma 9.9
736 adrenal cortical adenocarcinoma 9.9
737 carcinosarcoma 9.9
738 superficial basal cell carcinoma 9.9
739 fibrous histiocytoma 9.9
740 dysgerminoma 9.9
741 pleomorphic adenoma 9.9
742 angiokeratoma 9.9
743 sebaceous adenocarcinoma 9.9
744 postpoliomyelitis syndrome 9.9
745 elephantiasis 9.9
746 hobnail hemangioma 9.9
747 small intestinal sarcoma 9.9
748 pneumonia 9.9
749 kidney disease 9.9
750 pediatric lymphoma 9.9
751 malignant peripheral nerve sheath tumor 9.9
752 congestive heart failure 9.9
753 bronchitis 9.9
754 follicular dendritic cell sarcoma 9.9
755 severe combined immunodeficiency 9.9
756 progressive multifocal leukoencephalopathy 9.9
757 adrenal adenoma 9.9
758 adenoma 9.9
759 pseudosarcomatous fibromatosis 9.9
760 muscular atrophy 9.9
761 laryngeal disease 9.9
762 myocarditis 9.9
763 tertiary syphilis 9.9
764 periodontitis 9.9
765 peritonitis 9.9
766 appendicitis 9.9
767 intestinal obstruction 9.9
768 ileus 9.9
769 paralytic ileus 9.9
770 actinomycosis 9.9
771 monocytic leukemia 9.9
772 herpes zoster 9.9
773 subacute delirium 9.9
774 smallpox 9.9
775 dermatophytosis 9.9
776 leishmaniasis 9.9
777 cutaneous leishmaniasis 9.9
778 amyloidosis 9.9
779 pemphigus 9.9
780 pulmonary embolism 9.9
781 encephalitis 9.9
782 meibomian cyst 9.9
783 47,xyy 9.9
784 sickle cell disease 9.9
785 acute monoblastic leukemia 9.9
786 chromosomal triplication 9.9
787 congenital human immunodeficiency virus 9.9
788 embryonal sarcoma 9.9
789 fibromatosis 9.9
790 giant cell myocarditis 9.9
791 granulocytopenia 9.9
792 ichthyosis, acquired 9.9
793 immunoglobulin g deficiency 9.9
794 mycobacterium avium complex infections 9.9
795 perniosis 9.9
796 prurigo nodularis 9.9
797 remitting seronegative symmetrical synovitis with pitting edema 9.9
798 secondary adrenal insufficiency 9.9
799 t-cell prolymphocytic leukemia 9.9
800 weber syndrome 9.9
801 raynaud phenomenon 9.9
802 encephalopathy 9.9
803 headache 9.9
804 hypotonia 9.9
805 posttransplant acute limbic encephalitis 9.9
806 combined immunodeficiency due to crac channel dysfunction 9.9
807 angioosteohypertrophic syndrome 9.9
808 epithelioid hemangioendothelioma 9.9
809 chronic actinic dermatitis 9.9
810 verrucous hemangioma 9.9
811 plastic bronchitis 9.9
812 hiv-associated cancer 9.9
813 argyria 9.9
814 rare vascular disease 9.9
815 hyperpigmentation of the skin 9.9
816 nodular lymphocyte predominant hodgkin lymphoma 9.9
817 overgrowth syndrome 9.9
818 hhv-8-associated multicentric castleman disease 9.9
819 intestinal polyposis syndrome 9.9
820 mesothelioma, malignant 9.9
821 antigen defined by monoclonal antibody aj9 9.9
822 pernicious anemia 9.9
823 pigmented purpuric eruption 9.9
824 polykaryocytosis inducer 9.9
825 porphyria cutanea tarda 9.9
826 schistosoma mansoni infection, susceptibility/ 9.9
827 scleroderma, familial progressive 9.9
828 hair whorl 9.9
829 felty syndrome 9.9
830 factor viii deficiency 9.9
831 exostoses, multiple, type i 9.9
832 cardiac arrhythmia 9.9
833 progressive familial heart block, type ia 9.9
834 down syndrome 9.9
835 tuberous sclerosis 1 9.9
836 lung cancer 9.9
837 celiac disease 1 9.9
838 chondrosarcoma 9.9
839 factor v deficiency 9.9
840 multiple pterygium syndrome, lethal type 9.9
841 xeroderma pigmentosum, complementation group a 9.9
842 xeroderma pigmentosum, variant type 9.9
843 hemophilia a 9.9
844 immunodeficiency with hyper-igm, type 1 9.9
845 gallbladder disease 1 9.9
846 progressive familial heart block, type ib 9.9
847 diamond-blackfan anemia 2 9.9
848 hypereosinophilic syndrome, idiopathic 9.9
849 hydrops, lactic acidosis, and sideroblastic anemia 9.9
850 t-cell lymphoma, subcutaneous panniculitis-like 9.9
851 angina pectoris 9.9
852 livedoid vasculitis 9.9
853 exanthema subitum 9.9
854 extrapulmonary tuberculosis 9.9
855 peripheral t-cell lymphoma 9.9
856 splenic marginal zone lymphoma 9.9
857 cd40 ligand deficiency 9.9
858 immunoglobulin alpha deficiency 9.9
859 good syndrome 9.9
860 nonbacterial thrombotic endocarditis 9.9
861 microscopic colitis 9.9
862 ileocolitis 9.9
863 angular cheilitis 9.9
864 salmonellosis 9.9
865 infantile myofibromatosis 9.9
866 renal hypoplasia 9.9
867 dedifferentiated liposarcoma 9.9
868 parotitis 9.9
869 endocarditis 9.9
870 glucose intolerance 9.9
871 rickets 9.9
872 mastitis 9.9
873 portal hypertension 9.9
874 megacolon 9.9
875 diphtheria 9.9
876 dysgammaglobulinemia 9.9
877 bladder sarcoma 9.9
878 trachea sarcoma 9.9
879 acute kidney tubular necrosis 9.9
880 paronychia 9.9
881 right bundle branch block 9.9
882 porphyria 9.9
883 urethritis 9.9
884 necrotizing ulcerative gingivitis 9.9
885 schistosomiasis 9.9
886 toxic megacolon 9.9
887 endodermal sinus tumor 9.9
888 cerebral palsy 9.9
889 hepatitis d 9.9
890 intestinal perforation 9.9
891 coccidiosis 9.9
892 brain sarcoma 9.9
893 myeloproliferative neoplasm 9.9
894 granulomatous hepatitis 9.9
895 nocardiosis 9.9
896 gastroenteritis 9.9
897 arteriosclerosis 9.9
898 myelophthisic anemia 9.9
899 glomangioma 9.9
900 chronic conjunctivitis 9.9
901 trachea leiomyoma 9.9
902 relapsing polychondritis 9.9
903 larynx cancer 9.9
904 transitional cell carcinoma 9.9
905 skin sarcoma 9.9
906 middle lobe syndrome 9.9
907 cryoglobulinemia 9.9
908 churg-strauss syndrome 9.9
909 keratoacanthoma 9.9
910 teratoma 9.9
911 embryonal carcinoma 9.9
912 systemic mastocytosis 9.9
913 mastocytosis 9.9
914 mast cell neoplasm 9.9
915 extramedullary plasmacytoma 9.9
916 arthropathy 9.9
917 bladder urothelial carcinoma 9.9
918 parasitic ectoparasitic infectious disease 9.9
919 neuromuscular disease 9.9
920 seminoma 9.9
921 extracutaneous mastocytoma 9.9
922 aggressive systemic mastocytosis 9.9
923 adenosquamous lung carcinoma 9.9
924 sclerosing hemangioma 9.9
925 poliomyelitis 9.9
926 ureteral obstruction 9.9
927 demyelinating polyneuropathy 9.9
928 central nervous system vasculitis 9.9
929 inflammatory leiomyosarcoma 9.9
930 testicular yolk sac tumor 9.9
931 paget's disease of bone 9.9
932 central pontine myelinolysis 9.9
933 acral lentiginous melanoma 9.9
934 skin tag 9.9
935 sarcomatoid penile squamous cell carcinoma 9.9
936 influenza 9.9
937 localized scleroderma 9.9
938 genital herpes 9.9
939 seborrheic dermatitis 9.9
940 granuloma inguinale 9.9
941 amebiasis 9.9
942 exophthalmos 9.9
943 hemorrhoid 9.9
944 keloid disorder 9.9
945 acquired hemophilia 9.9
946 allergic angiitis 9.9
947 angiomyomatous hamartoma 9.9
948 bone marrow necrosis 9.9
949 chronic graft versus host disease 9.9
950 collagenous gastritis 9.9
951 diffuse mesangial sclerosis 9.9
952 erythroplakia 9.9
953 glioma 9.9
954 haemophilus influenzae 9.9
955 hemorrhagic proctocolitis 9.9
956 herpes zoster ophthalmicus 9.9
957 human t-cell leukemia virus type 2 9.9
958 lymphangiectasis 9.9
959 lymphangiomatosis 9.9
960 lymphoma, large-cell, immunoblastic 9.9
961 lymphomatoid granulomatosis 9.9
962 lymphosarcoma 9.9
963 med23 9.9
964 muscular dystrophy white matter spongiosis 9.9
965 oral lichen planus 9.9
966 pituitary stalk interruption syndrome 9.9
967 rheumatoid vasculitis 9.9
968 testicular seminoma 9.9
969 tetraploidy 9.9
970 undifferentiated connective tissue disease 9.9
971 cryptogenic cirrhosis 9.9
972 postherpetic neuralgia 9.9
973 rare systemic disease 9.9
974 glial tumor 9.9
975 smoldering systemic mastocytosis 9.9
976 inflammatory myopathy with abundant macrophages 9.9
977 rare hemorrhagic disorder 9.9
978 diffuse alveolar hemorrhage 9.9
979 pemphigus erythematosus 9.9
980 polyploidy 9.9
981 parkinson disease, late-onset 9.8
982 chromosome 2q35 duplication syndrome 9.8
983 thyroid cancer, nonmedullary, 1 9.8
984 hashimoto thyroiditis 9.8
985 atrial standstill 1 9.8
986 acanthosis nigricans 9.8
987 wt limb-blood syndrome 9.8
988 anemia, hypochromic microcytic, with iron overload 1 9.8
989 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
990 familial mediterranean fever 9.8
991 osteogenic sarcoma 9.8
992 pituitary hormone deficiency, combined, 2 9.8
993 sjogren syndrome 9.8
994 budd-chiari syndrome 9.8
995 autoimmune lymphoproliferative syndrome 9.8
996 mitochondrial phosphate carrier deficiency 9.8
997 intraocular pressure quantitative trait locus 9.8
998 histiocytoma, angiomatoid fibrous 9.8
999 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 9.8
1000 bacterial sepsis 9.8
1001 hypochromic microcytic anemia 9.8
1002 hepatocellular adenoma 9.8
1003 fibroma 9.8
1004 aphasia 9.8
1005 lung abscess 9.8
1006 chronic myelomonocytic leukemia 9.8
1007 chronic urticaria 9.8
1008 cholelithiasis 9.8
1009 hemiplegia 9.8
1010 primary hyperparathyroidism 9.8
1011 disseminated intravascular coagulation 9.8
1012 heart disease 9.8
1013 pericardium cancer 9.8
1014 hyperandrogenism 9.8
1015 ecthyma 9.8
1016 bronchopneumonia 9.8
1017 quadriplegia 9.8
1018 mikulicz disease 9.8
1019 necrotizing sialometaplasia 9.8
1020 color blindness 9.8
1021 hyperparathyroidism 9.8
1022 facial paralysis 9.8
1023 urticaria 9.8
1024 thrombocytopenia due to platelet alloimmunization 9.8
1025 pericarditis 9.8
1026 islet cell tumor 9.8
1027 hypogonadism 9.8
1028 neuroma 9.8
1029 enthesopathy 9.8
1030 sensory peripheral neuropathy 9.8
1031 glycogen storage disease 9.8
1032 glucosephosphate dehydrogenase deficiency 9.8
1033 iga glomerulonephritis 9.8
1034 gallbladder cancer 9.8
1035 neurilemmoma 9.8
1036 thymic carcinoma 9.8
1037 turner syndrome 9.8
1038 solitary osseous plasmacytoma 9.8
1039 myopathy 9.8
1040 radiculopathy 9.8
1041 erdheim-chester disease 9.8
1042 schnitzler syndrome 9.8
1043 rhinitis 9.8
1044 large cell carcinoma 9.8
1045 skin hemangioma 9.8
1046 mesangial proliferative glomerulonephritis 9.8
1047 intrahepatic cholangiocarcinoma 9.8
1048 chronic inflammatory demyelinating polyradiculoneuropathy 9.8
1049 pulmonary coin lesion 9.8
1050 dystonia 9.8
1051 retinal disease 9.8
1052 median neuropathy 9.8
1053 rectum neuroendocrine neoplasm 9.8
1054 paraplegia 9.8
1055 hypersplenism 9.8
1056 cerebrovascular disease 9.8
1057 carotid artery occlusion 9.8
1058 chordoid meningioma 9.8
1059 polycythemia 9.8
1060 mucormycosis 9.8
1061 collagen disease 9.8
1062 peliosis hepatis 9.8
1063 lymphangitis 9.8
1064 scotoma 9.8
1065 hypopituitarism 9.8
1066 dacryoadenitis 9.8
1067 latent syphilis 9.8
1068 bronchiectasis 9.8
1069 hypoglycemia 9.8
1070 dendritic cell tumor 9.8
1071 lymphomatous thyroiditis 9.8
1072 parsonage turner syndrome 9.8
1073 pulmonary hyalinizing granuloma 9.8
1074 pulmonary sequestration 9.8
1075 retroperitoneal fibrosis 9.8
1076 rosai-dorfman disease 9.8
1077 aneurysm 9.8
1078 systemic autoimmune disease 9.8
1079 virus-associated trichodysplasia spinulosa 9.8
1080 epstein-barr virus-associated malignant lymphoproliferative disorder 9.8
1081 hepatoportal sclerosis 9.8
1082 thyroid tumor 9.8
1083 salivary gland disease 9.8
1084 reticulosarcoma 9.8
1085 chorioretinitis 9.8
1086 pachyonychia congenita 3 9.8

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Human phenotypes related to Kaposi Sarcoma:

58 31 (showing 54, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent herpes 58 31 obligate (100%) Obligate (100%) HP:0005353
2 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
3 hypermelanotic macule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001034
4 abnormality of the lower limb 58 31 hallmark (90%) Very frequent (99-80%) HP:0002814
5 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
6 hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0001028
7 abnormality of the spleen 58 31 frequent (33%) Frequent (79-30%) HP:0001743
8 abnormality of the gastrointestinal tract 58 31 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0011024
9 papule 58 31 frequent (33%) Frequent (79-30%) HP:0200034
10 encephalopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001298
11 skin nodule 58 31 frequent (33%) Frequent (79-30%) HP:0200036
12 generalized lymphadenopathy 58 31 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0008940
13 abnormal retinal morphology 58 31 frequent (33%) Frequent (79-30%) HP:0000479
14 lymphoproliferative disorder 58 31 frequent (33%) Frequent (79-30%) HP:0005523
15 fatigue 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0012378
16 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
17 lymphedema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001004
18 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
19 weight loss 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0001824
20 abnormal lung morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002088
21 venous insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0005293
22 abnormality of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0001392
23 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
24 skin plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0200035
25 nausea and vomiting 58 Occasional (29-5%)
26 renal insufficiency 58 Very rare (<4-1%)
27 anemia 58 Frequent (79-30%)
28 thrombocytopenia 58 Very rare (<4-1%)
29 jaundice 58 Occasional (29-5%)
30 hematuria 58 Very rare (<4-1%)
31 abdominal pain 58 Frequent (79-30%)
32 dyspnea 58 Very rare (<4-1%)
33 neoplasm 31 HP:0002664
34 cough 58 Occasional (29-5%)
35 macule 58 Very frequent (99-80%)
36 mediastinal lymphadenopathy 58 Frequent (79-30%)
37 intestinal obstruction 58 Very rare (<4-1%)
38 lymphadenopathy 58 Very frequent (99-80%)
39 elevated c-reactive protein level 58 Frequent (79-30%)
40 edema 31 HP:0000969
41 abdominal distention 58 Occasional (29-5%)
42 elevated erythrocyte sedimentation rate 58 Frequent (79-30%)
43 restrictive cardiomyopathy 58 Very rare (<4-1%)
44 follicular hyperplasia 58 Frequent (79-30%)
45 myelofibrosis 58 Very rare (<4-1%)
46 ureteral obstruction 58 Very rare (<4-1%)
47 decreased mean corpuscular volume 58 Occasional (29-5%)
48 anasarca 58 Very rare (<4-1%)
49 constitutional symptom 58 Frequent (79-30%)
50 neoplasm by anatomical site 58 Occasional (29-5%)
51 abdominal mass 58 Occasional (29-5%)
52 increased serum interleukin-6 58 Frequent (79-30%)
53 flank pain 58 Occasional (29-5%)
54 kaposi's sarcoma 31 HP:0100726

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema

Clinical features from OMIM®:

148000 (Updated 05-Apr-2021)

UMLS symptoms related to Kaposi Sarcoma:


fever; pruritus; exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

46 (showing 15, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 AKT1 CDK6 FGF2 IFNB1 IL6 IL6ST
2 immune system MP:0005387 10.34 AKT1 CCR8 CDK6 IFNB1 IL6 IL6ST
3 cardiovascular system MP:0005385 10.33 AKT1 CDK6 FGF2 IL6 IL6ST IRF3
4 cellular MP:0005384 10.31 AKT1 CDK6 FGF2 IL6 IL6ST IRF3
5 liver/biliary system MP:0005370 10.2 AKT1 CDK6 IL6 IL6ST MYC PDGFB
6 embryo MP:0005380 10.18 AKT1 CDK6 IL6ST MYC PDGFB STAT3
7 integument MP:0010771 10.18 AKT1 IL6 IL6ST MYC PDGFB STAT3
8 nervous system MP:0003631 10.18 AKT1 CCR8 CDK6 FGF2 IFNB1 IL6
9 neoplasm MP:0002006 10.1 AKT1 CDK6 FGF2 IFNB1 IL6 IL6ST
10 muscle MP:0005369 10.09 AKT1 CDK6 FGF2 IL6 MYC PDGFB
11 normal MP:0002873 9.97 AKT1 CCR8 IFNB1 IL6ST MYC STAT3
12 reproductive system MP:0005389 9.96 AKT1 CDK6 FGF2 IL6 IL6ST MYC
13 respiratory system MP:0005388 9.81 AKT1 IL6 IRF3 PDGFB STAT3 STIM1
14 skeleton MP:0005390 9.65 AKT1 FGF2 IFNB1 IL6 IL6ST MYC
15 vision/eye MP:0005391 9.32 CDK6 FGF2 IL6 IL6ST IRF3 PDGFB

Drugs & Therapeutics for Kaposi Sarcoma

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 152, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Lopinavir Approved Phase 4 192725-17-0 92727
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
9
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
14
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Immunosuppressive Agents Phase 4
20 Immunologic Factors Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antifungal Agents Phase 4
23 Calcineurin Inhibitors Phase 4
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
26
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
27 Anti-Retroviral Agents Phase 3
28 Anti-HIV Agents Phase 3
29 Reverse Transcriptase Inhibitors Phase 3
30 Dideoxynucleosides Phase 2, Phase 3
31 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
32
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
33
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
34
Didanosine Approved Phase 2 69655-05-6 50599
35
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
36
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
37
Indinavir Approved Phase 2 150378-17-9 5362440